Brief: Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Lisata Therapeutics

16/07/2024 13:17

July 16 (Reuters) - Lisata Therapeutics Inc  LSTA.O :
    * LISATA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
ITS
PHASE 2A BOLSTER TRIAL OF CERTEPETIDE IN FIRST-LINE
CHOLANGIOCARCINOMA
    * LISATA THERAPEUTICS INC - TOP-LINE DATA NOW ANTICIPATED
MID-2025
    * LISATA THERAPEUTICS INC: COMPLETE ENROLLMENT ACHIEVED
NEARLY SIX
MONTHS AHEAD OF PLAN
    * LISATA THERAPEUTICS INC - ADDITION OF SECOND-LINE
CHOLANGIOCARCINOMA ARM TO BOLSTER TRIAL

Source text for Eikon:  ID:nGNXbJrHcL 
Further company coverage:  LSTA.O 

 ((Reuters.Briefs@thomsonreuters.com;))